SOURCES SOUGHT
B -- Testing the efficacy of candidate Alzheimer�s disease treatments in rescuing impaired hippocampal synaptic plasticity
- Notice Date
- 7/7/2021 4:58:00 PM
- Notice Type
- Sources Sought
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- HHS-NIH-NIDA(AG)-SBSS-75N95021Q00286
- Response Due
- 7/21/2021 8:00:00 AM
- Archive Date
- 08/05/2021
- Point of Contact
- Fred Ettehadieh
- E-Mail Address
-
Fred.Ettehadieh@nih.gov
(Fred.Ettehadieh@nih.gov)
- Description
- This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. �An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition.� It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract.� Responses will not be considered as proposals or quotes.� No award will be made as a result of this notice.� The Government will NOT be responsible for any costs incurred by the respondents to this notice.� This notice is strictly for research and information purposes only. Background and Objectives: � There is currently a pressing need to identify effective treatments for Alzheimer�s disease (AD). With the repeated failures of multiple pivotal phase-III clinical trials in patients with AD, it is critical to test novel methods of discovering disease-modifying AD treatments. As part of an ongoing study called the Drug Repurposing for Effective Alzheimer�s Medicines (DREAM) study, the National Institute on Aging (NIA) is testing whether exposure to commonly prescribed, FDA-approved drugs will be associated with protection against AD. DREAM will test approximately 20 drugs that we have nominated as �candidate AD treatments.� We will select the most promising drugs from the DREAM study that lower AD risk for in vivo efficacy studies in a transgenic mouse model of AD. In the proposed acquisition, we will test the efficacy of the most promising drugs emerging from the DREAM study and ongoing proteomic/metabolomic studies in the NIA IRP to rescue impaired hippocampal synaptic plasticity. This will be accomplished by studying their effects on late long term potentiation (LTP) in hippocampal slices obtained from the APP/PS1 transgenic AD mouse model. Research in the NIA has identified several Food and Drug Administration approved drugs that may target metabolic abnormalities associated with AD and be of utility as effective disease-modifying treatments. �Repurposing of approved drugs for AD is a promising approach that can accelerate the development of novel AD treatments. �As part of the DREAM study, we will perform pharmacoepidemiologic analyses of approximately 20 FDA approved drugs to test whether older individuals exposed to these �candidate AD treatments� are at lower risk of AD. �In parallel with these analyses, we also test whether these drugs ameliorate pathological changes associated with AD at the cellular level. In the next stage of these analyses, we propose to select the most promising drug(s) for testing as disease-modifying AD treatments by assessment of their efficacy in rescuing impaired hippocampal synaptic plasticity using the APP/PS1 transgenic mouse model of AD. Project Requirements: Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed. The main objective of the requirement is: 1. Perform in vitro electrophysiological recordings on hippocampal slice preparations from the APP/PS1 AD mouse model and corresponding wild type animal controls in order to test whether candidate AD drugs rescue impairment in late LTP known to occur in this well-characterized AD mouse model. 2. Perform statistical analyses to test whether a candidate AD drug(s) significantly restores impairment in hippocampal synaptic plasticity relative to the vehicle control. 3. Perform additional biochemical/western blot analyses to establish plausible pharmacological mechanisms of drug action associated with rescue of hippocampal plasticity by a drug(s). Anticipated Period of Performance:� Twenty-four (24) months. Capability Statement/information sought: Small business concerns that believe they possess the capabilities to provide the required services should submit documentation of their ability to meet each of the project requirements to the Contracting Officer. The capability statement must specifically address each of the project requirements separately.� Additionally, the capability statement should include 1) the total number of employees, 2) the professional qualifications of personnel as it relates to the requirements outlined, 3) any contractor GSA Schedule contracts by which all of the requirements may be met, if applicable, and 4) any other information considered relevant to this program. Small businesses must also provide their Company Name, DUNS number, Physical Address, and Point of Contact Information. Interested small businesses are required to identify their type of business, applicable North American Industry Classification System Code, and size standards in accordance with the Small Business Administration. The government requests that no proprietary or confidential business data be submitted in a response to this notice. However, responses that indicate the information therein is proprietary will be properly safeguarded for Government use only. Capability statements must include the name and telephone number of a point of contact having authority and knowledge to discuss responses with Government representatives. Capability statements in response to this market survey that do not provide sufficient information for evaluation will be considered non-responsive. When submitting this information, reference the solicitation notice number. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2� x 11� paper size, with 1� top, bottom, left and right margins, and with single or double spacing. The information submitted must be in an outline format that addresses each of the elements of the project requirements and in the capability statement /information sought paragraphs stated herein.� A cover page and an executive summary may be included but is not required. The response is limited to ten (10) pages.� The 10-page limit does not include the cover page, executive summary, or references, if requested. All capability statements sent in response to this Small Business Sources Sought Notice must be submitted to Fred Ettehadieh, Contracting Officer, by email at fred.ettehadieh@nih.gov before the closing date and time of this announcement. All responses must be received by the specified due date and time in order to be considered. Facsimile responses are not acceptable. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in the response.� No proprietary, classified, confidential, or sensitive information should be included in your response.� The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate.� Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization�s qualifications to perform the work.� Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted.� After review of the responses received, pre-solicitation and solicitation notices may be published in Federal Business Opportunities.� However, responses to this notice will not be considered adequate responses to a solicitation.� The solicitation release date is pending.� Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/5cc055ea56c042baa84db4bdd110190f/view)
- Record
- SN06054138-F 20210709/210707230120 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |